MX339209B - Composiciones. - Google Patents

Composiciones.

Info

Publication number
MX339209B
MX339209B MX2012014335A MX2012014335A MX339209B MX 339209 B MX339209 B MX 339209B MX 2012014335 A MX2012014335 A MX 2012014335A MX 2012014335 A MX2012014335 A MX 2012014335A MX 339209 B MX339209 B MX 339209B
Authority
MX
Mexico
Prior art keywords
buprenorphine
sustained release
flowable composition
delivery system
release delivery
Prior art date
Application number
MX2012014335A
Other languages
English (en)
Other versions
MX2012014335A (es
Inventor
Mingxing Zhou
Richard L Norton
Andrew Watkins
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339209(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of MX2012014335A publication Critical patent/MX2012014335A/es
Publication of MX339209B publication Critical patent/MX339209B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención está dirigida a un sistema de suministro de liberación sostenida de buprenorfina capaz de suministrar buprenorfina, un metabolito, o un profármaco de la misma por una duración de alrededor de 14 días hasta alrededor de 3 meses. El sistema de suministro de liberación sostenida de buprenorfina incluye una composición fluida y un implante sólido para la liberación sostenida de buprenorfina, un metabolito, o un profármaco de la misma. El implante se produce de la composición fluida. El sistema de suministro de liberación sostenida de buprenorfina proporciona perfiles de liberación in situ de 1 mes y 3 meses caracterizados por una biodisponibilidad excepcionalmente alta y riesgo mínimo de daño al tejido permanente y típicamente sin riesgo de necrosis en el músculo.
MX2012014335A 2010-06-08 2011-06-06 Composiciones. MX339209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (2)

Publication Number Publication Date
MX2012014335A MX2012014335A (es) 2013-03-05
MX339209B true MX339209B (es) 2016-04-15

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014335A MX339209B (es) 2010-06-08 2011-06-06 Composiciones.

Country Status (31)

Country Link
US (1) US8921387B2 (es)
EP (3) EP3360538B1 (es)
JP (2) JP5986072B2 (es)
KR (1) KR101865689B1 (es)
CN (1) CN103079544B (es)
AU (1) AU2011263478B2 (es)
BR (1) BR112012031290A2 (es)
CA (1) CA2801676C (es)
CL (1) CL2012003462A1 (es)
CO (1) CO6670529A2 (es)
CY (1) CY1120761T1 (es)
DK (2) DK3360538T3 (es)
ES (2) ES2656938T3 (es)
FI (1) FI3360538T3 (es)
GB (2) GB2481018B (es)
HR (1) HRP20180118T1 (es)
HU (1) HUE038275T2 (es)
IL (2) IL223488A (es)
LT (1) LT2579874T (es)
MX (1) MX339209B (es)
MY (1) MY171625A (es)
NO (1) NO2579874T3 (es)
NZ (1) NZ604026A (es)
PL (1) PL2579874T3 (es)
PT (1) PT2579874T (es)
RS (1) RS56820B1 (es)
RU (1) RU2607498C2 (es)
SG (1) SG186200A1 (es)
SI (1) SI2579874T1 (es)
WO (1) WO2011154724A2 (es)
ZA (1) ZA201209233B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
WO2013156850A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
IL296882A (en) * 2012-07-26 2022-12-01 Camurus Ab Opioid compounds
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
US20150320866A1 (en) * 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
KR102370470B1 (ko) * 2013-03-15 2022-03-04 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2015164283A1 (en) * 2014-04-21 2015-10-29 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
KR102450730B1 (ko) 2014-04-21 2022-10-05 헤론 테라퓨틱스 인코포레이티드 장기간 작용하는 중합체 전달 시스템
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2015168031A1 (en) 2014-04-28 2015-11-05 OrphoMed LLC Buprenorphine dimer and its use in treatment of gastrointestinal disorders
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
EA036951B1 (ru) * 2015-08-03 2021-01-19 Толмар Интернэшнл Лимитед Жидкая полимерная система доставки для длительного введения лекарственных средств
PL3377041T3 (pl) 2015-11-16 2024-03-11 Medincell S.A. Sposób morselizacji i/lub kierowania farmaceutycznie aktywnych składników do tkanki maziowej
CN109789137B (zh) * 2016-09-13 2023-01-13 昱展新药生技股份有限公司 丁丙诺啡缓释制剂
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
CA3089114A1 (en) 2018-01-22 2019-07-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ES2171186T3 (es) 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
BR0315304A (pt) * 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
BR112012031290A2 (pt) 2016-11-01
GB2481018A (en) 2011-12-14
NO2579874T3 (es) 2018-06-09
GB2513267A (en) 2014-10-22
CN103079544A (zh) 2013-05-01
EP4218720A1 (en) 2023-08-02
JP5986072B2 (ja) 2016-09-06
CA2801676C (en) 2018-08-07
IL223488A (en) 2017-10-31
AU2011263478B2 (en) 2015-01-22
KR101865689B1 (ko) 2018-06-08
RU2607498C2 (ru) 2017-01-10
DK3360538T3 (da) 2023-03-06
DK2579874T3 (da) 2018-01-29
US8921387B2 (en) 2014-12-30
HUE038275T2 (hu) 2018-10-29
HRP20180118T1 (hr) 2018-03-09
GB2481018B (en) 2015-03-18
NZ604026A (en) 2015-01-30
GB201413064D0 (en) 2014-09-03
KR20130135026A (ko) 2013-12-10
ZA201209233B (en) 2014-04-30
WO2011154724A3 (en) 2012-07-12
GB201009549D0 (en) 2010-07-21
JP2013533230A (ja) 2013-08-22
WO2011154724A9 (en) 2012-08-16
WO2011154724A2 (en) 2011-12-15
LT2579874T (lt) 2018-02-12
ES2656938T3 (es) 2018-03-01
EP3360538A1 (en) 2018-08-15
ES2939612T3 (es) 2023-04-25
US20130210853A1 (en) 2013-08-15
RU2012157244A (ru) 2014-07-20
MX2012014335A (es) 2013-03-05
CL2012003462A1 (es) 2013-04-01
CN103079544B (zh) 2017-06-09
FI3360538T3 (fi) 2023-03-22
CY1120761T1 (el) 2019-12-11
SI2579874T1 (en) 2018-03-30
PT2579874T (pt) 2018-01-29
JP2016155865A (ja) 2016-09-01
AU2011263478A1 (en) 2013-01-10
CO6670529A2 (es) 2013-05-15
MY171625A (en) 2019-10-21
GB2513267B (en) 2015-03-18
PL2579874T3 (pl) 2018-05-30
RS56820B1 (sr) 2018-04-30
CA2801676A1 (en) 2011-12-15
EP2579874B1 (en) 2018-01-10
SG186200A1 (en) 2013-01-30
EP3360538B1 (en) 2023-02-15
EP2579874A2 (en) 2013-04-17
JP6251774B2 (ja) 2017-12-20
IL254417A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
MY171625A (en) Injectable flowable composition comprising buprenorphine
BR112012031288A2 (pt) composições
UA105496C2 (uk) Доставка октреотиду сухими фармакологічними формами
WO2010149727A3 (en) Injectable formulations containing asenapine and method of treatment using same
IN2012DN02735A (es)
IN2012DN02702A (es)
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CR20110110A (es) Composicion farmaceutica
MY175800A (en) Combination treatment of cancer
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MY161595A (en) Oral care compositions
UA99540C2 (ru) Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
EP2649033A4 (en) COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONES COMPOUNDS
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
WO2012170417A3 (en) Methods and compositions to enhance bone growth comprising a statin
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EP3442503A4 (en) INJECTABLE COMPOSITION FOR THE ADMINISTRATION OF A BIOLOGICAL ACTIVE SUBSTANCE
PH12017502149A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
MX2013013691A (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
HK1141451A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
JO3394B1 (ar) تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: ANTISOMA RESEARCH LIMITED